Disease · MONDO_0005855

molluscum contagiosum

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. molluscum contagiosum. Diseases, record MONDO_0005855. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005855

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: molluscum contagiosum; Open Targets
Open Targets ID: MONDO_0005855; Open Targets
Disease Ontology: DOID:8867; Disease Ontology
MeSH: D008976; MeSH
Highest stage of its drugs: Approval, for 2 of its 8 drugs, from FDA; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CANTHARIDIN	CHEMBL48449	Small molecule	Approval	FDA	8	6	6	Drugs and targets
BERDAZIMER SODIUM	CHEMBL4298064	Small molecule	Approval	FDA	4	3	3	Drugs and targets
ADAPALENE	CHEMBL1265	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BENZOYL PEROXIDE	CHEMBL1200370	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
VEHICLE	CHEMBL2108661		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
POTASSIUM HYDROXIDE	CHEMBL2103983	Small molecule	Phase 2/3	ClinicalTrials.gov	3	3	3	Drugs and targets
INGENOL MEBUTATE	CHEMBL1863513	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
ACYCLOVIR	CHEMBL184	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets3

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
RARA	Retinoic acid receptor	1	Retinoic acid receptor agonist	Phase 3	https://conductscience.org/library/genes/5914	Drugs and targets
RARB	Retinoic acid receptor	1	Retinoic acid receptor agonist	Phase 3	https://conductscience.org/library/genes/5915	Drugs and targets
RARG	Retinoic acid receptor	1	Retinoic acid receptor agonist	Phase 3	https://conductscience.org/library/genes/5916	Drugs and targets

Trials16

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04535531	A Phase 3 Molluscum Contagiosum Efficacy and Safety Study	Phase 3	891	2023-01-26	Molluscum Contagiosum	VEHICLE	Its record names the disease	ClinicalTrials.gov
NCT03927703	A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC	Phase 3	355	2023-01-20	Molluscum Contagiosum	BERDAZIMER SODIUM	Its record names the disease	ClinicalTrials.gov
NCT03927716	A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)	Phase 3	352	2022-12-27	Molluscum Contagiosum	BERDAZIMER SODIUM	Its record names the disease	ClinicalTrials.gov
NCT03377790	Cantharidin Application in Molluscum Patients-1	Phase 3	266	2021-12-14	Molluscum Contagiosum	CANTHARIDIN	Its record names the disease	ClinicalTrials.gov
NCT03377803	Cantharidin Application in Molluscum Patients	Phase 3	262	2021-12-14	Molluscum Contagiosum	CANTHARIDIN	Its record names the disease	ClinicalTrials.gov
NCT03436615	A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum	Phase 2	256	2023-05-06	Molluscum Contagiosum	BERDAZIMER SODIUM	Its record names the disease	ClinicalTrials.gov
NCT02665260	Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum	Phase 2	94	2017-05-05	Molluscum Contagiosum	CANTHARIDIN	Its record names the disease	ClinicalTrials.gov
NCT03186378	Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.	Phase 2	33	2021-08-09	Molluscum Contagiosum	CANTHARIDIN	Its record names the disease	ClinicalTrials.gov
NCT03017846	Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2	Phase 2	30	2019-01-30	Molluscum Contagiosum	CANTHARIDIN	Its record names the disease	ClinicalTrials.gov
NCT00667225	Efficacy of Cantharidin in Molluscum Contagiosum	Not applicable	29	2011-06-01	Molluscum Contagiosum, Skin Disease	CANTHARIDIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 16

See all 16 trials

Comparisons in its trials38

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
SB206 vs Placebo: Complete Clearance of All Treatable MC at Week 8	87 of 444	52 of 447	891	NCT04535531	Trial comparisons
SB206 vs Placebo: A Lesion Count of 0 or 1 of All Treatable MC at Week 12	193 of 444	110 of 447	891	NCT04535531	Trial comparisons
SB206 vs Placebo: 90% Reduction From Baseline in the Number of All Treatable MC at Week 12	191 of 444	107 of 447	891	NCT04535531	Trial comparisons
SB206 vs Placebo: Complete Clearance of All Treatable MC at Week 12	144 of 444	88 of 447	891	NCT04535531	Trial comparisons
SB206 vs Placebo: deaths from any cause	0 of 444	0 of 447	891	NCT04535531	Trial comparisons
SB206 vs Placebo: serious adverse events	0 of 444	1 of 447	891	NCT04535531	Trial comparisons
SB206 vs Placebo: Complete Clearance of All Treatable MC at Week 8	33 of 237	7 of 118	355	NCT03927703	Trial comparisons
SB206 vs Placebo: Complete Clearance of All Treatable MC at Week 12	71 of 237	24 of 118	355	NCT03927703	Trial comparisons
SB206 12% vs Placebo Comparator: deaths from any cause	0 of 237	0 of 117	354	NCT03927703	Trial comparisons
SB206 12% vs Placebo Comparator: serious adverse events	1 of 237	1 of 117	354	NCT03927703	Trial comparisons

1 to 10 of 38

See all 38 comparisons in its trials

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36287306	DERIVED	1	PubMed
35830173	DERIVED	1	PubMed
34976290	DERIVED	2	PubMed
34909721	DERIVED	2	PubMed
33599960	DERIVED	2	PubMed
33400412	DERIVED	1	PubMed
32965495	DERIVED	2	PubMed
22011376	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005855

GET https://conductscience.org/api/diseases/v1/MONDO_0005855/comparisons?page=2

API reference For AI assistants